|
|
| (46 intermediate revisions by 2 users not shown) |
| Line 3: |
Line 3: |
| {{CMG}}; {{AE}} {{Preeti}} | | {{CMG}}; {{AE}} {{Preeti}} |
|
| |
|
| {| class="wikitable"
| |
| |+
| |
| ! colspan="2" rowspan="2" |
| |
| ! rowspan="2" |Pathophysiology
| |
| ! rowspan="2" |Symptoms
| |
| ! rowspan="2" |Physical Examination
| |
| ! colspan="3" |Laboratory Findings
| |
| |-
| |
| !Immunochemistry
| |
| !Blood work
| |
| !Biospy
| |
| |-
| |
| |
| |
| |[[Diffuse large B-cell lymphoma]]]<ref name="Shipp2002">{{cite journal |doi=10.1038/nm0102-68 |pmid=11786909 |title=Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning |journal=Nature Medicine |volume=8 |issue=1 |pages=68–74 |year=2002 |last1=Shipp |first1=Margaret A. |last2=Ross |first2=Ken N. |last3=Tamayo |first3=Pablo |last4=Weng |first4=Andrew P. |last5=Kutok |first5=Jeffery L. |last6=Aguiar |first6=Ricardo C.T. |last7=Gaasenbeek |first7=Michelle |last8=Angelo |first8=Michael |last9=Reich |first9=Michael |last10=Pinkus |first10=Geraldine S. |last11=Ray |first11=Tane S. |last12=Koval |first12=Margaret A. |last13=Last |first13=Kim W. |last14=Norton |first14=Andrew |last15=Lister |first15=T. Andrew |last16=Mesirov |first16=Jill |last17=Neuberg |first17=Donna S. |last18=Lander |first18=Eric S. |last19=Aster |first19=Jon C. |last20=Golub |first20=Todd R. }}</ref><ref name="Rosenwald2002">{{cite journal |doi=10.1056/NEJMoa012914 |pmid=12075054 |title=The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma |journal=New England Journal of Medicine |volume=346 |issue=25 |pages=1937–47 |year=2002 |last1=Rosenwald |first1=Andreas |last2=Wright |first2=George |last3=Chan |first3=Wing C. |last4=Connors |first4=Joseph M. |last5=Campo |first5=Elias |last6=Fisher |first6=Richard I. |last7=Gascoyne |first7=Randy D. |last8=Muller-Hermelink |first8=H. Konrad |last9=Smeland |first9=Erlend B. |last10=Giltnane |first10=Jena M. |last11=Hurt |first11=Elaine M. |last12=Zhao |first12=Hong |last13=Averett |first13=Lauren |last14=Yang |first14=Liming |last15=Wilson |first15=Wyndham H. |last16=Jaffe |first16=Elaine S. |last17=Simon |first17=Richard |last18=Klausner |first18=Richard D. |last19=Powell |first19=John |last20=Duffey |first20=Patricia L. |last21=Longo |first21=Dan L. |last22=Greiner |first22=Timothy C. |last23=Weisenburger |first23=Dennis D. |last24=Sanger |first24=Warren G. |last25=Dave |first25=Bhavana J. |last26=Lynch |first26=James C. |last27=Vose |first27=Julie |last28=Armitage |first28=James O. |last29=Montserrat |first29=Emilio |last30=López-Guillermo |first30=Armando |display-authors=29 }}</ref><ref name="Colomo2003">{{cite journal |doi=10.1182/blood-2002-04-1286 |pmid=12393466 |title=Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma |journal=Blood |volume=101 |issue=1 |pages=78–84 |year=2002 |last1=Colomo |first1=L. |last2=López-Guillermo |first2=A |last3=Perales |first3=M |last4=Rives |first4=S |last5=Martínez |first5=A |last6=Bosch |first6=F |last7=Colomer |first7=D |last8=Falini |first8=B |last9=Montserrat |first9=E |last10=Campo |first10=E }}</ref><ref name="”seer”">National Cancer Institute. Surveillance, Epidemiology, and End Results Program 2015. http://seer.cancer.gov</ref><ref>Tilly H, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2015; 26: v116-v125</ref><ref name="”seer”2">National Cancer Institute. Surveillance, Epidemiology, and End Results Program 2015. http://seer.cancer.gov</ref><ref name="pmid27271843">{{cite journal| author=Korkolopoulou P, Vassilakopoulos T, Milionis V, Ioannou M| title=Recent Advances in Aggressive Large B-cell Lymphomas: A Comprehensive Review. | journal=Adv Anat Pathol | year= 2016 | volume= 23 | issue= 4 | pages= 202-43 | pmid=27271843 | doi=10.1097/PAP.0000000000000117 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27271843 }}</ref>
| |
| |Classified into 2 subtypes based on [[gene expression]] profiles:
| |
| *Germinal centre B-cell-like (GCB)
| |
| *Activated B-cell-like (ABC).
| |
| **B cell receptor (BCR) signalling
| |
| **B cell migration/adhesion
| |
| **Cell-cell interactions in immune niches
| |
| **Production and class-switching of immunoglobulins
| |
| |
| |
| * Mass/Lump
| |
| :* Rapidly enlarging [[lymph nodes]].
| |
| :* Painless
| |
| :* May be present in neck, groin or abdomen
| |
|
| |
|
| :* It is not uncommon to have [[lymphoma]] in extranodal sites. B symptoms :
| | ==References== |
| :* Fever
| | {{Reflist|2}} |
| :* Night sweats
| |
| :* weight loss
| |
| :
| |
| *
| |
| | | |
| * Non tender mass
| |
|
| |
|
| *
| | {{WH}} |
| |
| | {{WS}} |
| * [[Immunohistochemistry]](IHC)
| | [[Category: (name of the system)]] |
| ** CD20, CD3, CD5, CD45, CD10, BCL-2, BCl-6, MYC, IRF-4/ MUM-1, Ki-67
| |
| * Flow Cytometry Panel
| |
| ** Kappa/ Lambda, CD3, CD5, CD45, CD10, CD19, CD20
| |
| * [[Cytology]] (for primary CNS lymphoma only)
| |
| * [[Genetic testing]]
| |
| ** 8q24/''MYC'' [[translocations]]
| |
| ** Immunoglobulin genes clonally rearranged and hypermutated
| |
| ** Mutation of ''BCL6'', ''MYC'', ''[[PAX5]]'', ''[[PIM1]]'', ''[[RhoH]]''/''TTFn'', ''[[TP53]]'' genes
| |
| ** Translocations involving ''c-MYC'', ''BCL6'', and ''IgH'' gene.
| |
| | |
| *
| |
| |
| |
| * Neutropenia
| |
| * Anemia
| |
| * Hypergammaglobulinemia
| |
| * Screening tests for HCV, HBV and HIV.
| |
| |
| |
| | |
| ====Centroblastic====
| |
| *Medium-to-large-sized [[Lymphocyte|lymphocytes]]
| |
| *Monomorphic
| |
| ====Immunoblastic::====
| |
| *> 90% immunoblasts
| |
| *Trapezoid shaped large lymphoid cells with significant [[basophilic]] cytoplasm
| |
| ====Anaplastic:====
| |
| *Very large cells with a round, oval, or polygonal shape that may resemble Reed-Sternberg cells of Hodgkin's lymphoma or Anaplastic Large cell Lymphoma.
| |
| |-
| |
| |
| |
| |[[Follicular lymphoma]]
| |
| |
| |
| * Reciprocal translocation t(14;18)(q32;q21).
| |
| |
| |
| *[[Fever]]
| |
| *[[Weight loss]]
| |
| *[[Night sweats]]
| |
| *[[Skin rash]]
| |
| *[[Chest pain]]
| |
| *[[Abdominal pain]]
| |
| *[[Bone pain]]
| |
| *[[Cough]]
| |
| *[[Dyspnea]]
| |
| *Painless swelling in the neck, axilla, groin, thorax and abdomen
| |
| |
| |
| * [[Lymphadenopathy|Central and peripheral lymphadenopathy]]
| |
| * [[Splenomegaly]]
| |
| * [[Hepatomegaly]]
| |
| * [[Abdominal tenderness]]
| |
| | |
| * [[Seizures]]
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |
| |
| |[[Burkitt lymphoma]]
| |
| |
| |
| * Translocation of chromosome 8 ''[[myc]]'' locus with 3 possible partners (accounting for 90% of translocations):
| |
| ** The Ig heavy chain region on chromosome 14: t(8;14)
| |
| ** The kappa light chain locus on chromosome 2: t(2;8)
| |
| ** The lambda light chain locus on chromosome 22: t(8;22)
| |
| |
| |
| * [[Fever]]
| |
| * [[Night sweats]]
| |
| * Unexplained [[weight loss]]
| |
| * [[Swollen lymph nodes]] in the neck, axilla, or groin
| |
| |
| |
| * [[Proptosis]]
| |
| * Jaw mass
| |
| | |
| * [[Abdominal mass|Abdominal masses]]
| |
| * [[Ascites]]
| |
| | |
| * [[Lymphadenopathy|Peripheral lymphadenopathy]]
| |
| |
| |
| * [[CD19]]
| |
| * [[CD20]],
| |
| * [[CD22]]
| |
| * [[CD10]]
| |
| * BCL6.
| |
| * BCL2 and TdT.
| |
| |
| |
| |
| |
| :* Medium-sized (~1.5-2x the size of a RBC) with uniform size ("monotonous") -- '''key feature''' (i.e. tumor nuclei size similar to that of [[histiocytes]] or [[endothelial cells]])
| |
| :* Round nucleus
| |
| :* Small nucleoli
| |
| :* [[basophilic]] cytoplasm
| |
| :* Brisk mitotic rate and [[apoptotic]] activity
| |
| :* Cellular outline usually appears squared off
| |
| :* "Starry-sky pattern":
| |
| :** The ''stars'' in the pattern are tingible-body macrophages (macrophages containing [[apoptotic]] tumor cells)
| |
| :** The tumour cells are the ''sky''
| |
| |-
| |
| | rowspan="25" |B cell lymphoma
| |
| |[[Mantle cell lymphoma]]
| |
| |
| |
| * [[CD5 (protein)|CD5]] positive antigen in pregerminal center of B-cell
| |
| * [[Chromosomal translocation]] at '''t(11:14)'''
| |
| ** Over-express [[cyclin D1]]
| |
| |
| |
| * Stage IV disease
| |
| * B symptoms,
| |
| * Generalized lymphadenopathy
| |
| * Abdominal distention
| |
| * Fatigue
| |
| * Night sweats
| |
| * Weight Loss
| |
| * Extranodal involvement of gastrointtestinal (GI) tract, lungs, and central nervous system (CNS)
| |
| |
| |
| * Generalized lymphadenopathy
| |
| * Hepato-splenomegaly
| |
| * Mental Retardation
| |
| * Less commonly
| |
| ** Palpable masses in skin, breast, and salivary glands
| |
| |
| |
| * CD5<sup>+</sup>
| |
| * B-cell antigen positive
| |
| ** CD19
| |
| ** CD20
| |
| ** CD22
| |
| * Cyclin D1 is overexpressed.
| |
| |CBC
| |
| * Anemia and cytopenias are secondary to bone marrow infiltration
| |
| * Lymphocytosis > 4000/µL
| |
| * Elevated LDH
| |
| *
| |
| |
| |
| * Germinal centers filled by small-to-medium atypical lymphocytes.
| |
| * Nodular appearance may be evident from expansion of the mantle zone in 30-50% of patients early in the disease.
| |
| |-
| |
| |[[Nodal marginal zone B-cell lymphoma]]
| |
| |
| |
| * Arise from memory B cells. Include
| |
| ** Splenic marginal zone lymphoma
| |
| ** Nodal marginal zone lymphoma
| |
| ** Extranodal marginal zone lymphoma.
| |
| * Stimulation of antigen receptor by autoantigen and co-stimulatory molecule CD40.
| |
| |
| |
| * Depends largely on its location
| |
| * Gastric marginal zone lymphoma
| |
| ** Dyspepsia
| |
| ** Abdominal pain
| |
| ** Hemorrhage
| |
| * Chronic infectious conditions or autoimmune processes, such as
| |
| ** ''H pylori'' gastritis
| |
| ** Hashimoto thyroiditis
| |
| ** Sjögren syndrome.
| |
| |
| |
| |
| |
| * AE1/AE3
| |
| * B-cell markers CD20, CD79a, CD10, CD23, and bcl-2 are expressed
| |
| |
| |
| |
| |
| * Follicular cells in reactive zone
| |
| * Centrocyte like cells in marginal zone lymphoma
| |
| |-
| |
| |[[Splenic marginal zone lymphoma]]
| |
| |
| |
| * Clonal rearrangements of the [[immunoglobulin]] genes (heavy and light chains) .
| |
| ** Deletion 7q21-32
| |
| ** Translocations of the CDK6 gene located at 7q21.
| |
| |
| |
| |
| |
| |
| |
| * [[CD20]]
| |
| * [[CD79a]]
| |
| |
| |
| |
| |
| * [[B-cells]] replace the normal [[white pulp]] of the [[spleen]].
| |
| * The neoplastic cells compromise
| |
| ** Small [[lymphocytes]]
| |
| ** Transformed blasts
| |
| * S[[Sinus|inus]] invasion
| |
| * Epithelial histocytes
| |
| * Plasmacytic differentiation of neoplastic cells.
| |
| * '''Splenic Hilar Lymph Nodes'''
| |
| ** Involved hilar [[lymph nodes]] adjacent to the [[spleen]] show an effaced architecture without preservation of the [[marginal zone]] seen in the spleen
| |
| * '''Bone Marrow Biopsy'''
| |
| ** Splenic marginal zone lymphoma in [[bone marrow]] displays a nodular pattern with morphology similar to what is observed in the splenic [[hilar]] [[lymph nodes]].
| |
| |-
| |
| |[[Hairy cell leukemia]]
| |
| |
| |
| * Production of [[Cytokine|cytokines]], such as [[TNF alpha]] and IL-2R, provide important stimuli for [[malignant]] [[B cell|B cells]] proliferation in hairy cell leukemia.
| |
| ** The ''p38-MAPK-JNK'' cascade
| |
| ** The ''MEK-ERK'' cascade
| |
| ** The ''Phosphatidylinositol 3 kinase (PI3K)-AKT'' cascade
| |
| |
| |
| * [[Fever]]
| |
| * [[Night sweat|Night sweats]]
| |
| * [[Fatigue]]
| |
| * Easy [[bruising]] or [[bleeding]]
| |
| * Generalized weakness
| |
| * [[Weight loss]]
| |
| * Recurrent [[Infection|infections]]
| |
| * Early satiety
| |
| |
| |
| * [[Pallor]],
| |
| * [[Petechiae]]
| |
| * [[Splenomegaly]]
| |
| |
| |
| * [[Annexin A1]]
| |
| * [[CD20]]
| |
| * [[CD25]]
| |
| * [[CD103]]
| |
| * [[CD19]]
| |
| * [[CD11c]]
| |
| * [[FMC7]]
| |
| |
| |
| * Tartrate-resistant acid phosphatase positive
| |
| * CBC
| |
| ** Decreased [[hemoglobin]] concentration
| |
| ** Decreased [[platelets]] count
| |
| **
| |
| |
| |
| :* Small cells with "fried egg"-like appearance
| |
| :* Well-demarcated thread-like [[cytoplasmic]] extensions
| |
| :* Clear cytoplasm
| |
| :* Central round [[nucleus]]
| |
| :* Peri-nuclear clearing ("water-clear rim" appearance)
| |
| |-
| |
| |[[Multiple myeloma|Plasma cell myeloma]]
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |[[Chronic lymphocytic leukemia]] / [[Chronic lymphocytic leukemia|small lymphocytic lymphoma]]
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |[[Monoclonal B-cell lymphocytosis]]
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |[[B-cell prolymphocytic leukemia]]
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |[[Waldenström's macroglobulinemia|Waldenström's macroglubulinemia]]
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |[[Monoclonal gammopathy of undetermined significance]] (MGUS)
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |[[Heavy chain disease]]
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |Solitary plasmacytoma of bone
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |Extraosseous plasmacytoma
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |Monoclonal immunoglobulin deposition diseases
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |Extranodal marginal zone lymphoma of [[MALT lymphoma|mucosa-associated lymphoid tissue]] (MALT lymphoma)
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |Large B-cell lymphoma with IRF4 rearrangement
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |[[Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle center lymphoma]]
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |T-cell/histiocyte-rich large B-cell lymphoma
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |[[Lymphomatoid granulomatosis]]
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |[[Primary mediastinal large B-cell lymphoma|Primary mediastinal (thymic) large B-cell lymphoma]]
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |[[Intravascular large B-cell lymphoma]]
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |ALK1 large B-cell lymphoma
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |Plasmablastic lymphoma
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |[[Primary effusion lymphoma]]
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| | rowspan="6" |T cell lymphoma
| |
| |[[Mycosis fungoides]] / [[Sézary syndrome]]
| |
| |
| |
| * The [[tumor]] [[Cell (biology)|cells]] originate from [[memory T cells]] or [[skin]] homing [[CD4+ T cells]] expressing [[cutaneous]] [[lymphocyte]] [[antigen]] (CLA) and [[chemokine]] [[receptors]] [[CCR4]]<nowiki/>and CCR7.
| |
| * It is understood that cutaneous t cell lymphoma (maycosis fungoides, Sezary sydrome ) is the result of malignant T cell that derived from a mature CD41 CD45RO1 memory T cells.
| |
| |
| |
| * [[Epidermis (skin)|Epidermal]] [[atrophy]] or poikiloderma
| |
| | |
| * Generalized [[itching]]([[pruritus]])
| |
| * [[Pain]] in the affected area of the skin.
| |
| * [[Insomnia]]
| |
| * Red ([[erythematous]]) patches scattered over the [[skin]] of the [[trunk]] and the [[extremities]]
| |
| * [[Weight loss]]
| |
| * [[Lymphadenopathy]]
| |
| * [[Malaise]] and [[fatigue]]
| |
| * [[Anemia]]
| |
| * May progress to [[Sezary syndrome]] (Skin involvement plus hematogenous dissemination)
| |
| |
| |
| * Cutaneous manifestaions
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |-
| |
| |[[T-cell granular lymphocytic leukemia]]
| |
| |
| |
| * Disregulation of signaling pathways:
| |
| ** FAS/FAS-L
| |
| ** Phosphatidylinositol-3 kinase (PI3K),
| |
| ** Mitogen-activated proteinkinase/extracellular signal-regulated kinase (MAPK/ERK)
| |
| |
| |
| Symptoms of T-cell large granular lymphocyte leukemia may include the following:
| |
| * Generalised weakness and [[Fatigue (physical)|fatigue]]
| |
| * [[Anorexia]]
| |
| * Joint pain
| |
| * Night sweating
| |
| * [[Epistaxis]]
| |
| * [[Bone pain]]
| |
| * [[Dyspnea]]
| |
| |
| |
| * Usually appear pale and malnourished.
| |
| * Cardiac flow murmur
| |
| * High-grade fever
| |
| * [[Hepatomegaly]]
| |
| * [[Splenomegaly]]
| |
| |
| |
| * [[CD3]]+
| |
| * [[TCR]]αβ+
| |
| * [[CD4]]-
| |
| * [[CD8]]+
| |
| |
| |
| * Neutropenia
| |
| * Anemia
| |
| * Hypergammaglobulinemia
| |
| |
| |
| :* Clonal rearrangements of the [[T-cell receptor]] (TCR) gene
| |
| :* Chronic (> 6 months) elevation in large granular lymphocytes (LGLs) in the peripheral blood
| |
| :* Large granular lymphocyte count greater than 2.0 × 109/L
| |
| :* Lymphocytosis (typically 2-20x109/L)
| |
| |-
| |
| |[[Subcutaneous panniculitis-like T-cell lymphoma]]
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |}
| |